688192 Dizal
- 39.45
- +0.72+1.86%
Dizal News
Dizal Reveals New Findings From Biomarker Analysis, Highlighting Sunvozertinib as an Effective Treatment for Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Dizal (SSE:688192), a biopharmaceutical company committed to developing groundbreaking new medicines for the treatment of cancer and immunological...
2024 ASCO | Dizhe Pharmaceutical's latest exploratory biomarker analysis adds new data to Schwarzer's treatment of EGFR exon20ins mutant non-small cell lung cancer
Baseline plasma circulating tumor DNA (ctDNA) tests positive and negative epidermal growth factor receptor (EGFR) exon 20 (exon20ins) mutations were observed to benefit after receiving Schwarzhe treatment. Schwarzhe directly acts on the EGFR signaling pathway and can effectively remove the EGFR exon20ins mutation in plasma ctDNA. Schwarzell's drug resistance mechanism shows EGFR-dependent and EGFR-independent pathways. Goliximinib (JAK1 inhibitor) combined chemotherapy is a potential solution in Shanghai 2024 May 24
Digger Pharmaceuticals (688192.SH): Schwarzer's latest research results were selected for the 2024 American Society of Clinical Oncology Conference Report
Glonghui, May 24, 丨 Dizhe Pharmaceutical (688192.SH) announced that at the American Society of Clinical Oncology (ASCO) annual meeting to be held in Chicago from May 31 to June 4, 2024, the company will announce the two latest research results of its self-developed novel Class I lung cancer target drug Schwarzhe (generic name: sulvortinib tablets) targeting epidermal growth factor receptor (EGFR) exon 20 (exon20ins) mutant advanced non-small cell lung cancer (NSCLC). Among them is Schwarzer? Global Note on Treated EGFrexon20InS Mutant NSCLC
Downgrade: Here's How Analysts See Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHSE:688192) Performing In The Near Term
The latest analyst coverage could presage a bad day for Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHSE:688192), with the analysts making across-the-board cuts to their statutory estimates that might l
Dizhe Pharmaceutical (688192.SH): Chairman and others completed an increase in holdings of 6.59 million yuan
Zhitong Finance App News, Dizhe Pharmaceutical (688192.SH) announced that as of May 8, 2024, Dr. Zhang Xiaolin, Chairman and CEO of the company, Mr. Lu Hongbin, Secretary of the Board of Directors and Chief Financial Officer, and Ms. Wu Qingyi, Deputy General Manager and Chief Commercial Officer, have increased their holdings by 1991.88 million shares, accounting for 0.0479% of the company's total share capital, with a total increase of 6.597.42 million yuan. The plan to increase holdings has been completed.
These 4 Measures Indicate That Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Is Using Debt Reasonably Well
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Dizhe Pharmaceutical (688192.SH) announced first-quarter results with a net loss of 224 million yuan
Dizhe Pharmaceutical (688192.SH) released its report for the first quarter of 2024. During the reporting period, the company achieved an operating income of 8...
Dizhe Pharmaceutical (688192.SH) announced its 2023 annual results with a net loss of 1.08 billion yuan
Dizhe Pharmaceutical (688192.SH) released its 2023 annual performance report. During the reporting period, the company achieved an operating income of 9...
2024 CSCO guide major update! Schwarzhe was included in the Level I recommendation, and goliximitinib was recommended for the first time, breaking through the bottleneck of treating difficult tumor targets
SHANGHAI, April 27, 2024/PRNewswire/ -- From April 26 to 27, 2024, the Chinese Society of Clinical Oncology (CSCO) guidelines conference was held in Jinan. In the 2024 CSCO diagnosis and treatment guidelines released at this conference, the two original innovative drugs independently developed by Dizhe Pharmaceutical (stock code: 688192.SH), and golisitinib, were both included in the guidelines as recommended drugs. Schwarzhe was recommended by the “CSCO Guidelines for the Diagnosis and Treatment of Non-small Cell Lung Cancer (2024 Edition)” at Level I, which targets experience in this guideline
Breakthrough in Lung Cancer Treatment: Dizal to Unveil Groundbreaking Results of Sunvozertinib for Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations at 2024 ASCO Annual Meeting
Dizal (SSE:688192), a biopharmaceutical company committed to developing groundbreaking new medicines for the treatment of cancer and immunological...
FDA Grants Breakthrough Therapy Designation to Sunvozertinib for the First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
SHANGHAI, April 7, 2024 /PRNewswire/ -- Dizal (688192.SH) today announced that the U.S. Food and Drug Administration ("FDA") has granted Breakthrough Therapy Designation (BTD) to its sunvozertinib as
Digger Pharmaceuticals (688192.SH): Schwarzhe was recognized as a “breakthrough therapy” by the FDA
Dizhe Pharmaceutical (688192.SH) issued an announcement, and the company's product Suvorazhe (generic name: suvoritinib) was awarded by the United States...
Digger Pharmaceutical's advanced EGFR Ex20ins mutation frontline was once again recognized as a breakthrough therapy by the FDA, and the global registered clinical study was selected for the 2024 ASCO oral report
SHANGHAI, April 7, 2024/PRNewswire/ -- On April 7, 2024, Dizhe Pharmaceutical (stock code: 688192.SH) announced that the US Food and Drug Administration (FDA) granted breakthrough therapy certification for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) exon 20 (exon20ins) mutations. This is a follow-up to the advanced NSCL mutant of EGFR exon20ins
Dizal (Jiangsu) Pharmaceutical Co., Ltd.'s (SHSE:688192) Largest Shareholders Are Private Equity Firms Who Were Rewarded as Market Cap Surged CN¥1.4b Last Week
Key Insights Significant control over Dizal (Jiangsu) Pharmaceutical by private equity firms implies that the general public has more power to influence management and governance-related decisions A
Digel Pharmaceutical (688192.SH) Performance Report: Net loss of 1,123 billion yuan in 2023
Gelonghui, Feb. 23 | Digi Pharmaceutical (688192.SH) announced its 2023 annual performance report. During the reporting period, the company achieved total operating income of 91.2886 million yuan; net profit attributable to owners of the parent company - 1,123 million yuan; net profit attributable to owners of the parent company after deducting non-recurring profit and loss - 1,177 million yuan; basic earnings per share - 2.75 yuan
The chairman of Dizhe Pharmaceutical (688192.SH) increased his total holdings by 161,000 shares
Dizhe Pharmaceutical (688192.SH) issued an announcement. As of February 18, 2024, the company's chairman and chief...
Dizhe Pharmaceutical (688192.SH) forecasted losses and is expected to lose a huge loss of about 1,119 billion yuan in 2023
Dizhe Pharmaceutical (688192.SH) released its 2023 annual results forecast and is expected to operate in 2023...
Dizal (Jiangsu) Pharmaceutical Co., Ltd.'s (SHSE:688192) Intrinsic Value Is Potentially 31% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, Dizal (Jiangsu) Pharmaceutical fair value estimate is CN¥56.79 Dizal (Jiangsu) Pharmaceutical is estimated to be 23% undervalued based on cur
Dizal's Sunvozertinib Pivotal Study Results Published in The Lancet Respiratory Medicine
SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Dizal today announced that the results of a phase 2 pivotal study of sunvozertinib for the treatment of platinum-pretreated non-small-cell lung cancer (NSCLC)
Digger Pharmaceuticals (688192.SH): Schwogel's China Registration Research was published in “The Lancet · Respiratory Medicine”
Digel Pharmaceutical (688192.SH) issued an announcement. Recently, the company independently developed highly selective EGFR tyrosine...
Analysis
Price Target
No Data
